Abbott Laboratories Revenue 2012-2025 | ABT
Abbott Laboratories annual/quarterly revenue history and growth rate from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Abbott Laboratories revenue for the quarter ending September 30, 2025 was $11.369B, a 6.9% increase year-over-year.
- Abbott Laboratories revenue for the twelve months ending September 30, 2025 was $43.843B, a 6.37% increase year-over-year.
- Abbott Laboratories annual revenue for 2024 was $41.95B, a 4.59% increase from 2023.
- Abbott Laboratories annual revenue for 2023 was $40.109B, a 8.12% decline from 2022.
- Abbott Laboratories annual revenue for 2022 was $43.653B, a 1.34% increase from 2021.
|
Abbott Laboratories Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $41,950 |
| 2023 | $40,109 |
| 2022 | $43,653 |
| 2021 | $43,075 |
| 2020 | $34,608 |
| 2019 | $31,904 |
| 2018 | $30,578 |
| 2017 | $27,390 |
| 2016 | $20,853 |
| 2015 | $20,405 |
| 2014 | $20,247 |
| 2013 | $19,657 |
| 2012 | $19,050 |
| 2011 | $21,407 |
|
Abbott Laboratories Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $11,369 |
| 2025-06-30 | $11,142 |
| 2025-03-31 | $10,358 |
| 2024-12-31 | $10,974 |
| 2024-09-30 | $10,635 |
| 2024-06-30 | $10,377 |
| 2024-03-31 | $9,964 |
| 2023-12-31 | $10,241 |
| 2023-09-30 | $10,143 |
| 2023-06-30 | $9,978 |
| 2023-03-31 | $9,747 |
| 2022-12-31 | $10,091 |
| 2022-09-30 | $10,410 |
| 2022-06-30 | $11,257 |
| 2022-03-31 | $11,895 |
| 2021-12-31 | $11,468 |
| 2021-09-30 | $10,928 |
| 2021-06-30 | $10,223 |
| 2021-03-31 | $10,456 |
| 2020-12-31 | $10,701 |
| 2020-09-30 | $8,853 |
| 2020-06-30 | $7,328 |
| 2020-03-31 | $7,726 |
| 2019-12-31 | $8,314 |
| 2019-09-30 | $8,076 |
| 2019-06-30 | $7,979 |
| 2019-03-31 | $7,535 |
| 2018-12-31 | $7,765 |
| 2018-09-30 | $7,656 |
| 2018-06-30 | $7,767 |
| 2018-03-31 | $7,390 |
| 2017-12-31 | $7,589 |
| 2017-09-30 | $6,829 |
| 2017-06-30 | $6,637 |
| 2017-03-31 | $6,335 |
| 2016-12-31 | $5,333 |
| 2016-09-30 | $5,302 |
| 2016-06-30 | $5,333 |
| 2016-03-31 | $4,885 |
| 2015-12-31 | $5,188 |
| 2015-09-30 | $5,150 |
| 2015-06-30 | $5,170 |
| 2015-03-31 | $4,897 |
| 2014-12-31 | $5,356 |
| 2014-09-30 | $5,079 |
| 2014-06-30 | $5,057 |
| 2014-03-31 | $4,755 |
| 2013-12-31 | $4,008 |
| 2013-09-30 | $4,825 |
| 2013-06-30 | $5,446 |
| 2013-03-31 | $5,378 |
| 2012-12-31 | $3,188 |
| 2012-09-30 | $5,265 |
| 2012-06-30 | $5,313 |
| 2012-03-31 | $5,284 |
| 2011-12-31 | $10,377 |
| 2011-09-30 | $9,817 |
| 2011-06-30 | $9,616 |
| 2011-03-31 | $9,041 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $216.142B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EssilorLuxottica (ESLOY) | France | $149.893B | 0.00 |
| Boston Scientific (BSX) | United States | $139.557B | 31.91 |
| Stryker (SYK) | United States | $136.074B | 27.02 |
| Medtronic (MDT) | Ireland | $123.612B | 17.13 |
| Medline (MDLN) | United States | $56.293B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.245B | 0.00 |
| Agilent Technologies (A) | United States | $41.482B | 26.22 |
| GE HealthCare Technologies (GEHC) | United States | $38.615B | 18.47 |
| ResMed (RMD) | United States | $37.167B | 25.72 |
| Koninklijke Philips (PHG) | Netherlands | $28.531B | 18.64 |
| Terumo (TRUMY) | Japan | $21.128B | 23.78 |
| Insulet (PODD) | United States | $19.568B | 60.74 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.507B | 10.92 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.553B | 0.00 |
| Baxter (BAX) | United States | $10.101B | 8.15 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.690B | 31.25 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| BillionToOne (BLLN) | United States | $4.433B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.366B | 13.30 |
| Envista Holdings (NVST) | United States | $3.820B | 21.92 |
| Haemonetics (HAE) | United States | $3.690B | 16.42 |
| ICU Medical (ICUI) | United States | $3.661B | 23.24 |
| Prestige Consumer Healthcare (PBH) | United States | $3.111B | 14.19 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.262B | 14.54 |
| Perrigo (PRGO) | Ireland | $2.073B | 5.19 |
| Neogen (NEOG) | United States | $1.999B | 43.76 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 38.06 |
| AtriCure (ATRC) | United States | $1.810B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.784B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.742B | 76.36 |
| Phibro Animal Health (PAHC) | United States | $1.640B | 16.38 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.515B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.437B | 20.80 |
| Kestra Medical Technologies (KMTS) | United States | $1.286B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.151B | 341.43 |
| Capricor Therapeutics (CAPR) | United States | $1.133B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.054B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.028B | 0.00 |
| Omeros (OMER) | United States | $0.895B | 0.00 |
| InMode (INMD) | Israel | $0.887B | 10.02 |
| Valneva SE (VALN) | France | $0.864B | 0.00 |
| CeriBell (CBLL) | United States | $0.845B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.564B | 15.30 |
| Cerus (CERS) | United States | $0.484B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.476B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.472B | 0.00 |
| Brainsway (BWAY) | Israel | $0.467B | 79.45 |
| Canopy Growth (CGC) | Canada | $0.461B | 0.00 |
| SNDL (SNDL) | Canada | $0.434B | 0.00 |
| Evolus (EOLS) | United States | $0.371B | 0.00 |
| Quanterix (QTRX) | United States | $0.334B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.295B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 21.97 |
| Sanuwave Health (SNWV) | United States | $0.245B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.33 |
| TerrAscend (TSNDF) | Canada | $0.236B | 0.00 |
| High Tide (HITI) | Canada | $0.235B | 0.00 |
| Organigram Global (OGI) | Canada | $0.228B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanara MedTech (SMTI) | United States | $0.211B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.197B | 0.00 |
| Accendra Health (ACH) | United States | $0.194B | 1.95 |
| Utah Medical Products (UTMD) | United States | $0.188B | 16.54 |
| OraSure Technologies (OSUR) | United States | $0.187B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| Apyx Medical (APYX) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.135B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.117B | 0.00 |
| Exagen (XGN) | United States | $0.117B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.76 |
| Biote (BTMD) | United States | $0.111B | 4.86 |
| MacroGenics (MGNX) | United States | $0.111B | 0.00 |
| Sharps Technology (STSS) | United States | $0.061B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 25.58 |
| Nephros (NEPH) | United States | $0.047B | 34.00 |
| Cytosorbents (CTSO) | United States | $0.046B | 0.00 |
| Veru (VERU) | United States | $0.039B | 0.00 |
| Jin Medical (ZJYL) | China | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.57 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Bonk (BNKK) | United States | $0.014B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |